# Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer

> **NCT04381832** · PHASE1,PHASE2 · COMPLETED · sponsor: **Arcus Biosciences, Inc.** · enrollment: 173 (actual)

## Conditions studied

- Prostatic Neoplasms, Castration-Resistant
- Androgen-Resistant Prostatic Neoplasms
- Castration Resistant Prostatic Neoplasms
- Prostatic Cancer, Castration-Resistant

## Interventions

- **DRUG:** Etrumadenant
- **DRUG:** Zimberelimab
- **DRUG:** Quemliclustat
- **DRUG:** Enzalutamide
- **DRUG:** Docetaxel
- **DRUG:** SG

## Key facts

- **NCT ID:** NCT04381832
- **Lead sponsor:** Arcus Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-07
- **Primary completion:** 2024-08-30
- **Final completion:** 2024-08-30
- **Target enrollment:** 173 (ACTUAL)
- **Last updated:** 2025-07-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04381832

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04381832, "Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04381832. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*